Summary
Vertex Pharmaceuticals reported strong third-quarter 2021 results, driven by significant growth in product revenues, particularly from TRIKAFTA/KAFTRIO in the U.S. and Europe. Total revenues increased by 29% year-over-year to $1.98 billion. While net income saw a substantial increase of 28% to $851.9 million for the quarter, the nine-month period showed a decrease of 25% to $1.57 billion, largely due to a significant upfront payment of $900 million made to CRISPR Therapeutics for the CTX001 collaboration. The company maintains a robust liquidity position with over $6.9 billion in cash, cash equivalents, and marketable securities as of September 30, 2021. Investments in research and development remain high, reflecting Vertex's commitment to advancing its pipeline beyond cystic fibrosis into areas like sickle cell disease, beta thalassemia, and type 1 diabetes. The company continues to expand access to its cystic fibrosis treatments, with ongoing efforts for reimbursement in Canada and priority review for TRIKAFTA in younger age groups. Key pipeline developments include advancing Phase 3 trials for a new CF combination therapy and anticipating regulatory submissions for CTX001 in late 2022. Significant strategic collaborations with CRISPR Therapeutics and Moderna underscore Vertex's focus on both gene editing and mRNA technologies for future therapeutic advancements. Investors should note the substantial R&D investment, particularly the one-time payment to CRISPR, which impacted the year-to-date net income, while the core CF business demonstrates sustained growth.
Financial Highlights
49 data points| Revenue | $1.98B |
| Cost of Revenue | $236.50M |
| Gross Profit | $1.75B |
| R&D Expenses | $493.75M |
| SG&A Expenses | $198.20M |
| Operating Expenses | $929.60M |
| Operating Income | $1.05B |
| Net Income | $851.90M |
| EPS (Basic) | $3.30 |
| EPS (Diluted) | $3.28 |
| Shares Outstanding (Basic) | 257.90M |
| Shares Outstanding (Diluted) | 259.70M |
Key Highlights
- 1Total revenues increased 29% to $1.98 billion for the three months ended September 30, 2021, compared to $1.54 billion in the prior year period.
- 2Net income for the three months ended September 30, 2021, increased 28% to $851.9 million, or $3.28 per diluted share, from $667.4 million, or $2.53 per diluted share, in the prior year period.
- 3Nine months ended September 30, 2021, net income decreased 25% to $1.57 billion from $2.11 billion in the prior year period, primarily due to a $900 million upfront payment to CRISPR.
- 4Product revenues for TRIKAFTA/KAFTRIO increased significantly by 62% to $1.56 billion for the third quarter, driven by uptake in Europe and strong performance in the U.S.
- 5Cash, cash equivalents, and marketable securities stood at $6.96 billion as of September 30, 2021, indicating a strong liquidity position.
- 6Research and development expenses increased substantially by 73% year-over-year for the nine months ended September 30, 2021, largely due to the CRISPR collaboration payment.